Giandomenico Turchiano, Ph.D.

With the help of Synthego's synthetic sgRNA, we are able to achieve reliable high editing efficiencies in primary cells which is relieving. With Synthego products, we will develop CRISPR-Cas platform based technologies to establish clinical protocols with the goal of curing Hyper-immunoglobulin E syndrome (HIES) through a genetic intervention in patient-derived HSCs.